Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00181597 | Trilostane for Androgen-Independent Prostate Cancer | PHASE2 | COMPLETED | 24 | — | — | Mar 1, 2004 | Jan 1, 2006 | Dec 3, 2013 | 2 | United States |
| Name | Type | Description |
|---|---|---|
| Trilostane | DRUG | Taken orally once a day for three days then twice daily thereafter. |
| Hydrocortisone | DRUG | Taken orally with trilostane. |
Inclusion Criteria: * Histologically confirmed prostate adenocarcinoma * Disease progression despite androgen depravation therapy and antiandrogen withdrawal * Progressive measurable disease or bone scan progression or PSA progression * Serum total testosterone \< 50ng/ml * Creatinine \< 2.0 mg/dl ...